ID: MRFR/HC/6970-CR | 122 Pages | Author: Rahul Gotadki | November 2022
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS
4.2.2 INCREASING PREVALENCE OF VITLIGO
4.3 RESTRAINTS
4.3.1 LACK OF TRAINED PROFESSIONALS
4.4 OPPORTUNITIES
4.4.1 RISING NUMBER OF CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON REGION
5.3.3 IMPACT ON DEMAND AND SUPPLY
6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 SEGMENTAL VITILIGO
6.3 NON-SEGMENTAL VITILIGO
7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 THERAPY
7.2.1 DEPIGMENTATION
7.2.2 LIGHT
7.3 SURGERY
7.3.1 SKIN GRAFTING
7.3.2 BLISTER GRAFTING
7.3.3 MICRO-PIGMENTATION
7.4 MEDICATION
7.4.1 TOPICAL CORTICOSTEROIDS
7.4.2 IMMUNOSUPPRESSIVE
8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 AMBULATORY CLINICS
8.4 OTHERS
9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET
10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
10.6.2 MERGERS & ACQUISITIONS
10.7 MAJOR PLAYERS SALES ANALYSIS
10.7.1 SALES & OPERATING INCOME, 2021
10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2021
11 COMPANY PROFILE
11.1 INCYTE
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 BAUSCH HEALTH COMPANIES INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 KONINKLIJKE PHILIPS N.V.
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 DR. REDDY'S LABORATORIES LTD.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 STRATA SKIN SCIENCES
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 CLINUVEL PHARMACEUTICALS LTD
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 ISSAR PHARMACEUTICALS PVT. LTD.
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL ANALYSIS
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.
11.8.1 COMPANY OVERVIEWS
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 LIGHTSOURCES
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL ANALYSIS
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 ROIVANT SCIENCES LTD.
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL ANALYSIS
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 PRODUCTS OFFERED
11.10.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 3 GLOBAL VITILIGO TREATMENT MARKET, FOR SEGMENTAL VITILIGO, BY REGION, 2018–2030 (USD MILLION)
TABLE 4 GLOBAL VITILIGO TREATMENT MARKET, FOR NON-SEGMENTAL VITILIGO, BY REGION, 2018–2030 (USD MILLION)
TABLE 5 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 6 GLOBAL VITILIGO TREATMENT MARKET, FOR THERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 7 GLOBAL VITILIGO TREATMENT MARKET, FOR DEPIGMENTATION, BY REGION, 2018–2030 (USD MILLION)
TABLE 8 GLOBAL VITILIGO TREATMENT MARKET, FOR LIGHT, BY REGION, 2018–2030 (USD MILLION)
TABLE 9 GLOBAL VITILIGO TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)
TABLE 10 GLOBAL VITILIGO TREATMENT MARKET, FOR SKIN GRAFTING, BY REGION, 2018–2030 (USD MILLION)
TABLE 11 GLOBAL VITILIGO TREATMENT MARKET, FOR BLISTER GRAFTING, BY REGION, 2018–2030 (USD MILLION)
TABLE 12 GLOBAL VITILIGO TREATMENT MARKET, FOR MICRO-PIGMENTATION, BY REGION, 2018–2030 (USD MILLION)
TABLE 13 GLOBAL VITILIGO TREATMENT MARKET, FOR MEDICATION, BY REGION, 2018–2030 (USD MILLION)
TABLE 14 GLOBAL VITILIGO TREATMENT MARKET, FOR TOPICAL CORTICOSTEROIDS, BY REGION, 2018–2030 (USD MILLION)
TABLE 15 GLOBAL VITILIGO TREATMENT MARKET, FOR IMMUNOSUPPRESSIVE, BY REGION, 2018–2030 (USD MILLION)
TABLE 16 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 17 GLOBAL VITILIGO TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)
TABLE 18 GLOBAL VITILIGO TREATMENT MARKET, FOR AMBULATORY CLINICS, BY REGION, 2018–2030 (USD MILLION)
TABLE 19 GLOBAL VITILIGO TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 20 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION, 2018–2030 (USD MILLION)
TABLE 21 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 22 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 23 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 24 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 25 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 26 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 27 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 28 US: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 29 US: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 30 US: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 31 US: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 32 US: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 33 US: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 34 CANADA: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 35 CANADA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 36 CANADA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 37 CANADA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 38 CANADA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 39 CANADA: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 40 EUROPE: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 41 EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 42 EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 43 EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 44 EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 45 EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 46 EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 47 GERMANY: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 48 GERMANY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 49 GERMANY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 50 GERMANY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 51 GERMANY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 52 GERMANY: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 53 FRANCE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 54 FRANCE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 55 FRANCE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 56 FRANCE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 57 FRANCE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 58 FRANCE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 59 UK: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 60 UK: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 61 UK: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 62 UK: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 63 UK: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 64 UK: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 65 ITALY: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 66 ITALY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 67 ITALY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 68 ITALY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 69 ITALY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 70 ITALY: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 71 SPAIN: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 72 SPAIN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 73 SPAIN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 74 SPAIN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 75 SPAIN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 76 SPAIN: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 77 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 78 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)
TABLE 79 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 80 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 81 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)
TABLE 82 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 83 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY COUNTRY, 2023-2032 (USD MILLION)
TABLE 84 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 85 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 86 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 87 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 88 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 89 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 90 CHINA: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 91 CHINA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 92 CHINA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 93 CHINA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 94 CHINA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 95 CHINA: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 96 JAPAN: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 97 JAPAN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 98 JAPAN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 99 JAPAN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 100 JAPAN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 101 JAPAN: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 102 INDIA: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 103 INDIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 104 INDIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 105 INDIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 106 INDIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 107 INDIA: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 108 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 109 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 110 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 111 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 112 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 113 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 114 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 115 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 116 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 117 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 118 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 119 AUSTRALIA: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 120 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 121 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 122 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 123 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 124 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 125 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 126 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY COUNTRY, 2023-2032 (USD MILLION)
TABLE 127 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 128 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 129 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 130 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 131 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 132 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 133 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 134 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 135 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 136 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 137 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 138 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 139 AFRICA: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 140 AFRICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 141 AFRICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 142 AFRICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 143 AFRICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 144 AFRICA: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 145 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2023-2032 (USD MILLION)
TABLE 146 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 147 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 148 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2023-2032 (USD MILLION)
TABLE 149 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2023-2032 (USD MILLION)
TABLE 150 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 151 MAJOR MANUFACTURERS IN VITILIGO TREATMENT MARKET
TABLE 152 MOST ACTIVE PLAYER IN VITILIGO TREATMENT MARKET
TABLE 153 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
TABLE 154 MERGERS & ACQUISITIONS
TABLE 155 INCYTE: PRODUCTS OFFERED
TABLE 156 INCYTE: KEY DEVELOPMENTS
TABLE 157 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
TABLE 158 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
TABLE 159 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED
TABLE 160 STRATA SKIN SCIENCES: PRODUCTS OFFERED
TABLE 161 STRATA SKIN SCIENCES: KEY DEVELOPMENTS
TABLE 162 CLINUVEL PHARMACEUTICALS LTD: PRODUCTS OFFERED
TABLE 163 ISSAR PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED
TABLE 164 KERNEL MEDICAL EQUIPMENT CO., LTD.: PRODUCTS OFFERED
TABLE 165 LIGHTSOURCES: PRODUCTS OFFERED
TABLE 166 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 GLOBAL VITILIGO TREATMENT MARKET STRUCTURE
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 3 MARKET DYNAMICS: GLOBAL VITILIGO TREATMENT MARKET
FIGURE 4 DRIVERS: IMPACT ANALYSIS
FIGURE 5 RESTRAINT: IMPACT ANALYSIS
FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL VITILIGO TREATMENT MARKET
FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL VITILIGO TREATMENT MARKET
FIGURE 8 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2021 AND 2030 (USD MILLION)
FIGURE 9 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2021 AND 2030 (USD MILLION)
FIGURE 10 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2021 AND 2030 (USD MILLION)
FIGURE 11 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION 2021 AND 2030 (USD MILLION)
FIGURE 12 GLOBAL: VITILIGO TREATMENT MARKET SHARE (%), BY REGION, 2021
FIGURE 13 NORTH AMERICA: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY 2021
FIGURE 14 EUROPE: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY 2021
FIGURE 15 ASIA-PACIFIC: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 16 REST OF THE WORLD: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 18 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN VITILIGO TREATMENT MARKET
FIGURE 19 GLOBAL VITILIGO TREATMENT MARKET: COMPETITIVE LANDSCAPE
FIGURE 20 MAJOR PLAYERS SALES & OPERATING INCOME, 2021
FIGURE 21 MAJOR PLAYERS R&D EXPENDITURE, 2021
FIGURE 22 INCYTE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 INCYTE: SWOT ANALYSIS
FIGURE 24 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS
FIGURE 26 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS
FIGURE 28 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 DR. REDDY'S LABORATORIES LTD.: SWOT ANALYSIS
FIGURE 30 STRATA SKIN SCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 CLINUVEL PHARMACEUTICALS LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 CLINUVEL PHARMACEUTICALS LTD: SWOT ANALYSIS
FIGURE 33 ROIVANT SCIENCES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED
Vitiligo Treatment Market Segmentation
Vitiligo Treatment Type Outlook (USD Billion, 2018-2032)
Non-segmental Vitiligo
Segmental vitiligo
Vitiligo Treatment Type Outlook (USD Billion, 2018-2032)
Therapy
Surgery
Medication
Vitiligo Treatment End-User Outlook (USD Billion, 2018-2032)
Hospitals
Aesthetic Clinics
Vitiligo Treatment Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
North America Vitiligo Treatment by Type
Therapy
Surgery
Medication
North America Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
US Outlook (USD Billion, 2018-2032)
US Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
US Vitiligo Treatment by Type
Therapy
Surgery
Medication
US Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
CANADA Outlook (USD Billion, 2018-2032)
CANADA Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
CANADA Vitiligo Treatment by Type
Therapy
Surgery
Medication
CANADA Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Europe Outlook (USD Billion, 2018-2032)
Europe Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Europe Vitiligo Treatment by Type
Therapy
Surgery
Medication
Europe Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Germany Outlook (USD Billion, 2018-2032)
Germany Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Germany Vitiligo Treatment Type
Therapy
Surgery
Medication
Germany Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
France Outlook (USD Billion, 2018-2032)
France Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
France Vitiligo Treatment by Type
Therapy
Surgery
Medication
France Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
UK Outlook (USD Billion, 2018-2032)
UK Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
UK Vitiligo Treatment by Type
Therapy
Surgery
Medication
UK Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
ITALY Outlook (USD Billion, 2018-2032)
ITALY Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
ITALY Vitiligo Treatment by Type
Therapy
Surgery
Medication
ITALY Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
SPAIN Outlook (USD Billion, 2018-2032)
Spain Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Spain Vitiligo Treatment by Type
Therapy
Surgery
Medication
Spain Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
REST OF EUROPE Vitiligo Treatment by Type
Therapy
Surgery
Medication
REST OF EUROPE Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Asia-Pacific Vitiligo Treatment by Type
Therapy
Surgery
Medication
Asia-Pacific Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
China Outlook (USD Billion, 2018-2032)
China Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
China Vitiligo Treatment by Type
Therapy
Surgery
Medication
China Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Japan Outlook (USD Billion, 2018-2032)
Japan Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Japan Vitiligo Treatment by Type
Therapy
Surgery
Medication
Japan Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
India Outlook (USD Billion, 2018-2032)
India Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
India Vitiligo Treatment by Type
Therapy
Surgery
Medication
India Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Australia Outlook (USD Billion, 2018-2032)
Australia Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Australia Vitiligo Treatment by Type
Therapy
Surgery
Medication
Australia Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Rest of Asia-Pacific Vitiligo Treatment by Type
Therapy
Surgery
Medication
Rest of Asia-Pacific Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Rest of the World Vitiligo Treatment by Type
Therapy
Surgery
Medication
Rest of the World Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Middle East Outlook (USD Billion, 2018-2032)
Middle East Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Middle East Vitiligo Treatment by Type
Therapy
Surgery
Medication
Middle East Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Africa Outlook (USD Billion, 2018-2032)
Africa Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Africa Vitiligo Treatment by Type
Therapy
Surgery
Medication
Africa Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Latin America Outlook (USD Billion, 2018-2032)
Latin America Vitiligo Treatment by Type
Non-segmental Vitiligo
Segmental vitiligo
Latin America Vitiligo Treatment by Type
Therapy
Surgery
Medication
Latin America Vitiligo Treatment by End-User
Hospitals
Aesthetic Clinics
Research Methodology on Vitiligo Treatment Market
This research report on the vitiligo treatment market was created using a qualitative and quantitative research approach. The methodology involved the use and analysis of primary and secondary data obtained from market participants, including market analysts, industry experts, trade associations, academics, and regulatory and government bodies. The market estimates and forecasts were finalized by investing the collected data in an established forecasting model.
Primary Data Sources
The primary data sources were acquired from market participants via interviews and surveys. Data obtained from experts was mainly qualitative in nature and included insights and opinions about the vitiligo treatment market.
Secondary Data Sources
Secondary data were obtained from journals, trade associations, press releases, publications, market reports, SEC filings, and investor relations documents. Various web portals, such as Google Scholar, PubMed, and ClinicalTrials.gov were indeed used for sourcing secondary data. The secondary data sources were primarily used to identify the key market developments and initiatives undertaken by players in the vitiligo treatment market. Additionally, extensive secondary data analysis was conducted to validate the primary data collected and to gain a holistic view of the market.
Research Tools
For this market study, various market research tools were deployed to carry out an in-depth analysis and to obtain accurate market estimates and forecasts. SPSS (Statistical Package for the Social Sciences) software was used for creating and managing the datasets containing the collected primary and secondary data. The software was also used to carry out various statistical and algebraic operations. Furthermore, market matrices were used to compare the various product, price, and technology trends in the vitiligo treatment market. Market matrices were also employed to assess the potential of players in the market. Moreover, the strengths, weaknesses, opportunities, and threats (SWOT) analysis tool was applied to gain an understanding of the general competitive landscape of the vitiligo treatment market along with the market forecast for 2023 to 2030.
Data Triangulation
In order to validate the accuracy and reliability of the estimates and forecasts of the market size contained in the aforementioned report, a systematic process of data triangulation was undertaken. The major method used for triangulation in the study was simply comparing the results from different primary and secondary sources. Through data triangulation, it was possible to cross-check the data obtained from the source and arrive at highly accurate estimates and forecasts.
Market Share Analysis
The market share analysis involved the calculation of the market share of the market leaders in the treatment market using sales revenue and product portfolio analysis. Additionally, the primary and secondary data obtained from various sources were combined vitiligo to assess the market share analysis with a comprehensive view of the market.
Assumption
All of the data included in this report was collected in the form of surveys, secondary research, and in-person interviews. All of the data used to create estimates and forecasts had certain assumptions which are based on certain facts and figures. For instance, assumptions have been made in terms of the growth rate of the market during the forecast period. All of the assumptions have been thoroughly researched and documented before making the estimations and forecasts.